DOTAMIR (Phase III)

Investigator physician: Dr Elodie CHEVALIER

Pilot study evaluating somatostatin receptor PET imaging to detect inflammatory phases of myocarditis

Myocarditis

This is an interventional, prospective, non-randomized, single-center pilot study.
This study is based on the evaluation of an experimental drug (radiopharmaceutical, ⁶⁸Ga-DOTATOC) in the use of a medical device to detect the inflammatory phases of myocarditis. This radiopharmaceutical already has a marketing authorization (MA) for another indication (assessment of neuroendocrine tumors).
As part of the study, patients will receive 2 positron emission tomography scans combined with a PET/CT scan using ⁶⁸Ga-DOTATOC.

If this pilot study is positive, others could be scheduled to clarify the diagnostic value of PET/CT with ⁶⁸Ga-DOTATOC in this indication. Being able to confirm the still inflammatory and progressive nature of myocarditis could help guide specific treatment and monitoring measures, and thus prevent an unfavorable evolution.

The treatment under study: Diagnostic PET/CT ⁶⁸Ga-DOTATOC
Study status: Terminated
Clinical Trial number: NCT03347760
Funding: French East Organization funding